Resources

Type of publications
Regions
Diseases

5192 results found

2024 ∙ Domnich, A. Trombetta, C. S. Fallani, E. Salvatore, M.

Immunogenicity and safety of the MF59-adjuvanted seasonal influenza vaccine in non-elderly adults: A systematic review and meta-analysis

  • Adults
  • Influenza
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
High
2024 ∙ Ma, B. M. Tam, A. R. Chan, K. W. Hung, I. F. N. Tang, S. C. W. Chan, T. M. Yap, D. Y.

Immunogenicity and Safety of the Three-Dose COVID-19 Vaccine Regimen in Patients Receiving Renal Replacement Therapy: A Systematic Review and Meta-Analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Low
2024 ∙ Feng, S. McLellan, J. Pidduck, N. Roberts, N. Higgins, J. P. Choi, Y. Izu, A. Jit, M. Madhi, S. A. Mulholland, K. Pollard, A. J. Procter, S. Temple, B. Voysey, M.

Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis

  • Newborn
  • Children
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Ouyang, L. Lei, G. Gong, Y.

Immunogenicity of COVID-19 vaccines in patients with cirrhosis: A meta-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Kavikondala, S. Haeussler, K. Wang, X. Spellman, A. Bausch-Jurken, M. T. Sharma, P. Amiri, M. Krivelyova, A. Vats, S. Nassim, M. Kumar, N. Van de Velde, N.

Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Losa, L. Antonazzo, I. C. Di Martino, G. Mazzaglia, G. Tafuri, S. Mantovani, L. G. Ferrara, P.

Immunogenicity of Recombinant Zoster Vaccine: A Systematic Review, Meta-Analysis, and Meta-Regression

  • All age groups
  • Herpes zoster
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Moderate
2024 ∙ Chenchula, S. Chandra, M. B. Adusumilli, M. B. Ghanta, S. N. Bommasani, A. Kuttiappan, A. Padmavathi, R. Amerneni, K. C. Chikatipalli, R. Ghanta, M. K. Reddy, S. S. Mythili Bai, K. Prakash, S. Jogender, G. Chavan, M. Balakrishnan, S.

Immunogenicity, clinical efficacy and safety of additional second COVID-19 booster vaccines against Omicron and its subvariants: A systematic review

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Administration
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Chirasuthat, S. Ratanapokasatit, Y. Thadanipon, K. Chanprapaph, K.

Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines among Patients with Immune-Mediated Dermatological Diseases: A Systematic Review and Meta-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Low
2024 ∙ Sharifi Aliabadi, L. Azari, M. Taherian, M. R. Barkhordar, M. Abbas, S. A. M. Azari, M. Ahmadvand, M. Salehi, Z. Rouzbahani, S. Vaezi, M.

Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Low
2024 ∙ Vojtek, I. van Wouw, M. Thomson, A.

Impact of COVID-19 on vaccine confidence and uptake: A systematic literature review

  • All age groups
  • Acceptance
  • Coverage
Methodological quality (AMSTAR 2):
Not applicable
Loading...